Search results for "Brachytherapy boost"

showing 2 items of 2 documents

High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late, rectal toxicity

2017

PURPOSE: To determine the significance of dose-volume histogram parameters for predicting late rectal toxicity (LRT) after single-fraction high-dose-rate brachytherapy (HDRBT) boost and external beam radiotherapy (EBRT) in prostate cancer. MATERIALS AND METHODS: Three hundred patients with intermediate- or high-risk prostate cancer were included between August 2010 and March 2015. Treatment comprised a single-fraction HDRBT boost of 15.0 Gy plus EBRT (46.0 Gy delivered in 23 fractions) or an HDRBT boost of 9.5 Gy plus EBRT (60.0 Gy delivered in 30 fractions) if the seminal vesicles were infiltrated using real-time transrectal ultrasound-based planning. LRT was evaluated every 3 months after…

MaleOrgans at RiskDose-volume histogramTime Factorsmedicine.medical_treatmentBrachytherapyBrachytherapyRectumLate rectal toxicity030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancerOrgan at risk0302 clinical medicinemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesExternal beam radiotherapyRadiation InjuriesAgedAged 80 and overProstate cancerbusiness.industryRadiotherapy Planning Computer-AssistedBiologically equivalent doseRectumProstatic NeoplasmsCommon Terminology Criteria for Adverse EventsMiddle Agedmedicine.diseaseCombined Modality TherapyHigh-Dose Rate BrachytherapyHigh-dose-rate brachytherapy boostRadiation therapyDose-volume histogram parametermedicine.anatomical_structureOncology030220 oncology & carcinogenesisRegression AnalysisDose Fractionation RadiationNuclear medicinebusinessFollow-Up Studies
researchProduct

Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature.

2014

The intrinsic physical and radiobiological characteristics of High Dose Rate Brachytherapy (HDR-BT) are well suited to the treatment of prostate cancer. HDR-BT was initially used as a boost to external beam brachytherapy, but has subsequently been employed as the sole treatment, which is termed HDR monotherapy. This review summarizes the clinical outcomes and toxicity results of the principal studies and discusses the radiobiological basis supporting its use.

Malemedicine.medical_specialtymedicine.medical_treatmentBrachytherapyBrachytherapyProstate cancermedicineEffective treatmentHumansMedical physicsDose FractionationSalvage brachytherapySalvage TherapyProstate cancerbusiness.industryRadiobiologyProstatic NeoplasmsRadiotherapy DosageHDR-BTHematologymedicine.diseaseBrachytherapy boost; HDR-BT; High-dose rate brachytherapy; Prostate cancer; Radiobiology; Salvage brachytherapy; Dose Fractionation; Humans; Male; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome; Brachytherapy; Radiotherapy Dosage; Hematology; Oncology; Geriatrics and GerontologyHigh-Dose Rate BrachytherapyBrachytherapy boostTreatment OutcomeOncologyRadiologyDose Fractionation RadiationGeriatrics and GerontologybusinessHigh-dose rate brachytherapySalvage brachytherapyCritical reviews in oncology/hematology
researchProduct